BR112022021905A2 - Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo - Google Patents

Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo

Info

Publication number
BR112022021905A2
BR112022021905A2 BR112022021905A BR112022021905A BR112022021905A2 BR 112022021905 A2 BR112022021905 A2 BR 112022021905A2 BR 112022021905 A BR112022021905 A BR 112022021905A BR 112022021905 A BR112022021905 A BR 112022021905A BR 112022021905 A2 BR112022021905 A2 BR 112022021905A2
Authority
BR
Brazil
Prior art keywords
vaccine
polynucleotide
suffered
polypeptide
vector
Prior art date
Application number
BR112022021905A
Other languages
English (en)
Portuguese (pt)
Inventor
Brunsvik Fredriksen Agnete
Sekelja Monika
Schjetne Karoline
Norheim Gunnstein
Stubsrud Elisabeth
Original Assignee
Nykode Therapeutics ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nykode Therapeutics ASA filed Critical Nykode Therapeutics ASA
Publication of BR112022021905A2 publication Critical patent/BR112022021905A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112022021905A 2020-05-01 2021-05-03 Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo BR112022021905A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DKPA202070282 2020-05-01
DKPA202070293 2020-05-06
DKPA202070735 2020-11-05
DKPA202070820 2020-12-08
DKPA202170069 2021-02-15
PCT/EP2021/061602 WO2021219897A1 (en) 2020-05-01 2021-05-03 Betacoronavirus prophylaxis and therapy

Publications (1)

Publication Number Publication Date
BR112022021905A2 true BR112022021905A2 (pt) 2022-12-13

Family

ID=75870604

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021905A BR112022021905A2 (pt) 2020-05-01 2021-05-03 Vacina, polinucleotídeo, vetor, célula hospedeira, polipeptídeo, proteína dimérica, e, métodos para preparar a vacina e para tratar um sujeito que tem sofrido de uma infecção pelo betacoronavírus ou que está em necessidade de prevenção do mesmo

Country Status (11)

Country Link
US (1) US20230165952A1 (cg-RX-API-DMAC7.html)
EP (1) EP4143210A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023524054A (cg-RX-API-DMAC7.html)
KR (1) KR20230005962A (cg-RX-API-DMAC7.html)
CN (1) CN116096735A (cg-RX-API-DMAC7.html)
AU (1) AU2021262521A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022021905A2 (cg-RX-API-DMAC7.html)
CA (1) CA3176527A1 (cg-RX-API-DMAC7.html)
IL (1) IL297621A (cg-RX-API-DMAC7.html)
MX (1) MX2022013661A (cg-RX-API-DMAC7.html)
WO (1) WO2021219897A1 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
CN112028978B (zh) * 2020-09-07 2023-06-16 重庆医科大学 新冠病毒特异性cd8+t细胞表位肽及其应用
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
IL308310A (en) 2021-05-10 2024-01-01 Nykode Therapeutics ASA Co-expression of immune-stimulating structures and compounds
WO2022238432A2 (en) 2021-05-10 2022-11-17 Nykode Therapeutics ASA Co-expression of constructs and immunoinhibitory compounds
TW202334429A (zh) * 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
CN113801209B (zh) * 2021-11-16 2022-02-11 浙江普康生物技术股份有限公司 一种具有广谱中和活性的新型冠状病毒重组蛋白及其制备方法
GB202201765D0 (en) * 2022-02-11 2022-03-30 Virax Biolabs Uk Ltd Methods
CN114907452B (zh) * 2022-04-08 2023-07-25 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2病毒感染的M蛋白多肽
CN114832099B (zh) * 2022-04-08 2023-11-28 国科宁波生命与健康产业研究院 一种用于治疗SARS-CoV-2变异毒株感染的多肽制剂
LU102995B1 (en) * 2022-08-17 2024-02-19 PMCR GmbH Immunization against coronavirus
EP4572778A1 (en) * 2022-08-17 2025-06-25 Pmcr Gmbh Immunization against viral infections disease(s)
WO2024038157A1 (en) * 2022-08-17 2024-02-22 PMCR GmbH Immunization against coronavirus
WO2024044747A2 (en) * 2022-08-25 2024-02-29 University Of Florida Research Foundation, Inc. Immunogenic composition and uses thereof
WO2024092025A1 (en) 2022-10-25 2024-05-02 Nykode Therapeutics ASA Constructs and their use
US20260193669A1 (en) 2022-11-09 2026-07-09 Nykode Therapeutics ASA Co-Expression of Constructs and Polypeptides
EP4651892A2 (en) * 2023-01-20 2025-11-26 Duke University Epitope-scaffold immunogens for pancoronavirus vaccines
CN121263427A (zh) * 2023-04-07 2026-01-02 国立大学法人大阪大学 滤泡辅助性T细胞诱导性SARS-CoV-2刺突蛋白的部分肽
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
CN119143850A (zh) * 2024-08-20 2024-12-17 复旦大学 广谱抑制流感病毒的多肽及在预防和/或治疗流感病毒感染中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004215489B2 (en) * 2003-02-25 2010-07-15 Nykode Therapeutics ASA Modified antibody
WO2011161244A1 (en) * 2010-06-25 2011-12-29 Vaccibody As Homodimeric protein constructs
WO2012159643A1 (en) * 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP3533462A1 (en) 2011-12-21 2019-09-04 Vaccibody AS Vaccines against hpv
JP2019505512A (ja) * 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
MA47515A (fr) * 2017-02-16 2019-12-25 Modernatx Inc Compositions immunogènes très puissantes
EP3678699A1 (en) * 2017-09-07 2020-07-15 University Of Oslo Vaccine molecules
CN113631185A (zh) 2019-02-27 2021-11-09 尼克塔治疗公司 用于治疗癌症的免疫治疗组合
LT3972987T (lt) * 2020-04-10 2023-09-25 Akston Biosciences Corporation Antigenui specifinė imunoterapija, skirta sulietiems covid-19 baltymams ir naudojimo būdai
WO2021216954A1 (en) * 2020-04-23 2021-10-28 Alpha Beta Holdings, Llc Compositions and methods for treating or preventing virus infection

Also Published As

Publication number Publication date
IL297621A (en) 2022-12-01
MX2022013661A (es) 2022-11-30
KR20230005962A (ko) 2023-01-10
US20230165952A1 (en) 2023-06-01
CN116096735A (zh) 2023-05-09
AU2021262521A1 (en) 2022-12-08
JP2023524054A (ja) 2023-06-08
CA3176527A1 (en) 2021-11-04
WO2021219897A1 (en) 2021-11-04
EP4143210A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2022013661A (es) Vacuna y uso de la misma en la profilaxis y terapia de betacoronavirus.
Monschein et al. Vaccination and multiple sclerosis in the era of the COVID-19 pandemic
Treanor et al. Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+ GLA) adjuvant
Levin et al. Clinical evaluation of a novel microneedle device for intradermal delivery of an influenza vaccine: are all delivery methods the same?
BR112022014808A2 (pt) Composições e métodos para vacinas para prevenir e tratar infecção pelo coronavírus-sars-cov-2
BR112022013573A2 (pt) Vacinas universais contra imunógenos de organismos patogênicos que conferem proteção específica para organismo e entre grupos
BR112012018951C8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B8 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
Pedrazzoli et al. Vaccination for seasonal influenza in patients with cancer: recommendations of the Italian Society of Medical Oncology (AIOM)
BR112014021102A2 (pt) Anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
Jamshed et al. Improved immunogenicity of high-dose influenza vaccine compared to standard-dose influenza vaccine in adult oncology patients younger than 65 years receiving chemotherapy: a pilot randomized clinical trial
Block et al. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults
BR112018074152A8 (pt) Métodos para determinar um regime de dosagem, métodos para tratar um indivíduo, método para otimizar o tratamento terapeuticamente, agente terapêutico e sistema de rede para determinar uma dose eficaz ou um regime de dosagem para um indivíduo sendo tratado com um agente terapêutico
EA202091563A1 (ru) Человеческие антитела к гемагглютинину вируса гриппа
Camilloni et al. Antibody responses to intradermal or intramuscular MF59-adjuvanted influenza vaccines as evaluated in elderly institutionalized volunteers during a season of partial mismatching between vaccine and circulating A (H3N2) strains
Song et al. Long‐term and cross‐reactive immunogenicity of inactivated trivalent influenza vaccine in the elderly: MF59‐adjuvanted vaccine versus unadjuvanted vaccine
BR112023016241A2 (pt) Anticorpos que se ligam ao metapneumovírus, proteínas antigênicas de metapneumovírus e usos dos mesmos
Stapleton et al. High dose trivalent influenza vaccine compared to standard dose vaccine in patients with rheumatoid arthritis receiving TNF-alpha inhibitor therapy and healthy controls: results of the DMID 10-0076 randomized clinical trial
Triglav et al. Vaccination indications and limits in the elderly
Arakane et al. Superior immunogenicity profile of the new intradermal influenza vaccine compared to the standard subcutaneous vaccine in subjects 65 years and older: A randomized controlled phase III study
Arakane et al. Immunogenicity and safety of the new intradermal influenza vaccine in adults and elderly: A randomized phase 1/2 clinical trial
Rangappa Cytokine storm and immunomodulation in covid-19
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2
Hasegawa et al. Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses